Abstract:AML1-ETO oncoprotein (AE) resulting from t(8;21)(q22;q22) translocation is known to play a pivotal role in leukemogenesis of t(8;21) AML, yet the activating mutations or over-expression of C-KIT occur in half of the AML patients with t(8;21). Animal models have proven that activating C-KIT mutations cooperate with AE in causing overt AML. The aberrant C-KIT expression was thus thought to be the major “second hit” in stepwise leukemogenesis of t(8;21) AML. Previous studies have demonstrated that Eriocalyxin B (EriB), a diterpenoid extracted from Isodon eriocalyx , induced apoptosis in t(8;21) leukemia cells through the NF-κB and MAPK signaling pathways and triggered degradation of AE dependent on caspase-3. By targeting AML1-ETO oncoprotein and activating apoptosis pathways simultaneously, EriB has potential to treat the t(8;21) leukemia. In this study, we observed the synergistic effect of EriB and the chemotherapy drug Homoharringtonine (HHT) on Kasumi-1, an AML cell line harboring t(8;21) and C-KIT mutations. Compared with using EriB or HHT alone, the combination of EriB and HHT (E+H) exhibited a higher efficacy to induce apoptosis and inhibit proliferation of Kasumi-1 cells. Data further showed that HHT enhanced the AE degradation caused by EriB in a dose/time-dependent manner. In addition, HHT significantly decreased the expression of C-KIT in Kasumi-1 cells, and the combination with EriB markedly enhanced this effect. Mechanism study revealed that E+H combination down-regulated the expression of transcriptional factor Sp1 through up-regulating miR-29b, separated Sp1 protein from Sp1/NF-κB complex, and released the Sp1/NF-κB complex from the C-KIT promoter. These data point to a mechanism involving Sp1/NF-κB/miR-29b regulatory network whereby E+H combination down-regulate C-KIT mRNA expression. In addition, HHT induced a proteasome-mediated degradation of C-KIT protein, which was further enhanced by EriB. From these observations, we conclude that the combined use of EriB and HHT might offer a potential therapeutic avenue for t(8;21) AML with C-KIT mutations. Disclosures No relevant conflicts of interest to declare.

Eriocalyxin B induces apoptosis of t(8;21) leukemia cells through NF- κ B and MAPK signaling pathways and triggers degradation of AML1-ETO oncoprotein in a caspase-3-dependent manner

Eriocalyxin B induces apoptosis in lymphoma cells through multiple cellular signaling pathways.

A novel alkylating deacetylase inhibitor molecule EDO-S101 in combination with cytarabine synergistically enhances apoptosis of acute myeloid leukemia cells

Triptolide Down-regulates Bcr-abl Expression and Induces Apoptosis in Chronic Myelogenous Leukemia Cells

Erianin Suppresses the Development of Acute Myeloid Leukemia Via PPARɑ and Regulating PI3K/AKT Signaling Pathways

Molecular Mechanisms Underlying the Synergism of Erib and Hht in Treating T(8;21) AML with C-KIT Mutations

Combination of eriocalyxin B and homoharringtonine exerts synergistic anti-tumor effects against t(8;21) AML

Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo

Inducible Expression of Aml1-Eto Fusion Protein Endows Leukemic Cells with Susceptibility to Extrinsic and Intrinsic Apoptosis

Cytotoxic activity of lithospermum erythrorhizon root extract against childhood acute leukemia cells via regulation of PI3K/AKT/mTOR pathway

Co‐Targeting C‐myc and Bcl‐2 by Oral Small Molecule Combination of WBC100 and Venetoclax Effectively Controls Acute Myeloid Leukemia in Preclinical Models

Reinforced Erythroid Differentiation Inhibits Leukemogenic Potential of T(8;21) Leukemia

Targeting PI3K, Mtor, ERK, and Bcl-2 Signaling Network Shows Superior Antileukemic Activity Against AML

A natural acylphloroglucinol exerts anti-erythroleukemia effects via targeting STAT3 and p38-MAPK, and inhibiting PI3K/AKT/mTOR signaling pathway

Targeting of AML1-ETO in t(8;21) leukemia by oridonin generates a tumor suppressor-like protein.

The molecular mechanism of a novel derivative of BTO-956 induced apoptosis in human myelomonocytic lymphoma cells

Eriocalyxin B Blocks Human SW1116 Colon Cancer Cell Proliferation, Migration, Invasion, Cell Cycle Progression and Angiogenesis Via the JAK2/STAT3 Signaling Pathway.

leukemia in vitro and in vivo AML 1-ETO fusion protein and shows potent antitumor activity with low Oridonin , a diterpenoid extracted from medicinal herbs , targets

A novel iheyamine A derivative L42 suppresses acute myeloid leukemia via dual regulation of the PI3K/AKT/FOXO3a axis and TNF signaling pathway

Homoharringtonine Combined with Aclarubicin and Cytarabine Synergistically Induces Apoptosis in T(8;21) Leukemia Cells and Triggers Caspase-3-mediated Cleavage of the AML1-ETO Oncoprotein.

Calothrixin B derivatives induce apoptosis and cell cycle arrest on HEL cells through the ERK/Ras/Raf/MEK pathway